JDRF Statement on the Passage of the Inflation Reduction Act

“Insulin access is a matter of life or death for people with T1D, which is why it is unconscionable that 43 Members of the U.S. Senate voted today to strip away provisions from the budget bill to cap the out-of-pocket costs of insulin for those with commercial health insurance.

While the Senate removed the $35 per month cap for commercial plans, the Inflation Reduction Act still contains other critically important insulin affordability measures, including a Medicare provision to cap the monthly cost of insulin and limit overall drug costs to $2,000 per year. 

JDRF applauds the passage of the Inflation Reduction Act but will continue to urge the Senate to move swiftly to take up the INSULIN Act to ensure everyone has access to affordable insulin.”